<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603171</url>
  </required_header>
  <id_info>
    <org_study_id>KlinikumUM</org_study_id>
    <nct_id>NCT03603171</nct_id>
  </id_info>
  <brief_title>Clinical Outcome Measures in Myotonic Dystrophy Type 2</brief_title>
  <acronym>COMEDY-2</acronym>
  <official_title>Observational Trial in Myotonic Dystrophy Type 2 to Define Specific Clinical Outcome Measures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Benedikt Schoser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A monocentric, longitudinal, observational case-control study in patients with Myotonic
      Dystrophy type 2 (DM2). At least 60 DM2 will be evaluated through a battery of patients
      reported Outcomes (PROs) and clinical Outcome Measures (OMs), in order to define suitable OMs
      for DM2 and propose a disease specific severity scale. Patients will be re-evaluated after 6
      months. An age and gender-matched control cohort will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myotonic dystrophy type 2 (DM2) is an autosomal dominant, chronic progressive multisystemic
      disorder. Typical symptoms of DM2 include progressive proximal muscle weakness and wasting,
      often combined with axial and anterior neck muscles involvement, myotonia, muscular pain,
      fatigue and cataracts. The estimated prevalence is approximately 1 per 100,000 people, but in
      some nations as Germany the DM2 frequency is much higher than and close to 1.12.000. Compared
      to DM1 it has a relatively short history, as the genetic base and RNA pathogenesis have been
      clarified in 2003. In order to evaluate specific clinical aspects of DM2 and disease
      progression, the development and validation of ad-hoc tests is a unmet need in the
      neuromuscular field. Today, only a few outcome measures were used systematically in DM2
      patients, and none of them provide so far a validation of a clinical meaningful difference
      for an interventional clinical trial.

      The aims of this monocentric, observational, case-control study are:

        1. select and validate patient reported outcomes (PRO) and outcome measures (OM) in a large
           group of DM2 patient

        2. Propose a DM2-specific scale of disease severity

        3. collecting additional information regarding the phenotype and the progression of the
           disease;

        4. identify differences between subgroups (e.g. age, sex, years of disease).

      Participants will be recruited from the German-Swiss Registry for Myotonic Dystrophy and the
      internal database of the Friedrich-Baur-Institute (FBI), Department of Neurology,
      Ludwig-Maximilian-University, Munich, Germany. A total of at least 60 male and female
      patients with no age limit and with genetically proven DM2 will be included. Forty age and
      gender-matched controls will be also assessed.

      During the first evaluation of the DM2 and the controls group, the following PROs and OMs
      will be evaluated:

      General survey (Comorbidity, BMI, familiarity, onset, etcâ€¦), DM1-ActivC, R-Pact, FDSS, McGill
      pain questionnaire - short form, Brief pain inventory - short form, Beck depression
      inventory, Myotonia behaviour scale, Myotonia subscale from INQoL, Hand opening time,
      pressure pain threshold, manual and quantitative muscle testing, SARA scale, Berg balance
      scale, QMFT, GSGC, 30 second sit and stand test, FI-2 (only for upper extremities), 6-MWT.

      After six months a second evaluation of the DM2 group will be performed, in which all PROs
      and OMs except the general survey will be repeated.

      Data analysis will provide descriptive statistic and a complete validity and reliability
      informations. On the basis of these results, a disease specific severity scale will be
      proposed for the clinical use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quick motor function test (QMFT)</measure>
    <time_frame>6 months</time_frame>
    <description>A test for assessing motor function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DM1-ActivC</measure>
    <time_frame>6 months</time_frame>
    <description>A Rasch-built DM1 activity and participation scale for clinical use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R-PAct</measure>
    <time_frame>6 months</time_frame>
    <description>A Rasch-built Pompe-specific activity scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck depression inventory (BDI-II)</measure>
    <time_frame>6 months</time_frame>
    <description>A self-reported depression inventory administered verbally or self administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>McGill pain questionnaire (MPQ-sf)</measure>
    <time_frame>6 months</time_frame>
    <description>The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory Short-Form (BPI-sf)</measure>
    <time_frame>6 months</time_frame>
    <description>A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue and Daytime Sleepiness Scale (FDSS)</measure>
    <time_frame>6 months</time_frame>
    <description>A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myotonia Behaviour scale (MBS)</measure>
    <time_frame>6 months</time_frame>
    <description>It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)</measure>
    <time_frame>6 months</time_frame>
    <description>A subscale derived from the INQoL questionnaire. 3 questions regarding stiffness and myotonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand opening time</measure>
    <time_frame>6 months</time_frame>
    <description>A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale for Assessment and Rating of Ataxia (SARA)</measure>
    <time_frame>6 months</time_frame>
    <description>It is a clinical scale which assesses a range of different impairments in cerebellar ataxia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg balance scale (BBS)</measure>
    <time_frame>6 months</time_frame>
    <description>It is a 14 item objective measure designed to assess static balance and fall risk in adult populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain threshold (PPT)</measure>
    <time_frame>6 months</time_frame>
    <description>Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value oft wo measurements was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual muscle testing (MMT)</measure>
    <time_frame>6 months</time_frame>
    <description>The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two measurements is considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative muscle testing (QMT)</measure>
    <time_frame>6 months</time_frame>
    <description>Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference &gt; 10% between measurements, a third attempt is performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSGC</measure>
    <time_frame>6 months</time_frame>
    <description>GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Index-2 (only upper extremities)</measure>
    <time_frame>6 months</time_frame>
    <description>Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 seconds sit to stand test (30CST)</measure>
    <time_frame>6 months</time_frame>
    <description>It is a measurement that assesses functional lower extremity strength in older adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute-walking test (6MWT)</measure>
    <time_frame>6 months</time_frame>
    <description>It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MIRS-2</measure>
    <time_frame>10 months</time_frame>
    <description>Development of a muscle impairment staging score</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Myotonic Dystrophy Type 2</condition>
  <arm_group>
    <arm_group_label>DM2 group</arm_group_label>
    <description>Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls group</arm_group_label>
    <description>A group of gender and age-matched healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DM1-ActivC</intervention_name>
    <description>A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>R-PAct</intervention_name>
    <description>A Rasch-built Pompe-specific activity scale.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Beck depression inventory</intervention_name>
    <description>A self-reported depression inventory administered verbally or self administered.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>BDI-II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>McGill pain questionnaire</intervention_name>
    <description>The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>MPQ-sf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Brief Pain Inventory Short-Form</intervention_name>
    <description>A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>BPI-sf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fatigue and Daytime Sleepiness Scale</intervention_name>
    <description>A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>FDSS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Myotonia Behaviour scale</intervention_name>
    <description>It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>MBS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hand opening time</intervention_name>
    <description>A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pressure pain threshold</intervention_name>
    <description>Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>PPT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Manual muscle testing</intervention_name>
    <description>The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>MMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative muscle testing</intervention_name>
    <description>Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference &gt; 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>QMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Scale for Assessment and Rating of Ataxia</intervention_name>
    <description>SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>SARA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Berg balance scale</intervention_name>
    <description>It is a 14 item objective measure designed to assess static balance and fall risk in adult populations</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>BBS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quick motor function test</intervention_name>
    <description>Assessment of proximal motor function.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>QMFT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GSGC</intervention_name>
    <description>GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>30 seconds sit to stand test</intervention_name>
    <description>It is a measurement that assesses functional lower extremity strenght in older adults.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>30CST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Functional Index-2</intervention_name>
    <description>Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>FI-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Six minute walking test</intervention_name>
    <description>It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>6MWT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)</intervention_name>
    <description>A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.</description>
    <arm_group_label>DM2 group</arm_group_label>
    <arm_group_label>Healthy controls group</arm_group_label>
    <other_name>InQoL</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Myotonic Dystrophy type 2, without limitations regarding age of onset,
        disease duration or physical impairment related to the disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed myotonic dystrophy type 2

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Invalidating diseases not related with DM2 (e.g. Stroke).

          -  Subject participating in another clinical trial (other than registries) concurrently
             or within 30 days prior to screening for entry into this study.

          -  Unable to complete study questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedikt Schoser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Okkersen K, Jimenez-Moreno C, Wenninger S, Daidj F, Glennon J, Cumming S, Littleford R, Monckton DG, LochmÃ¼ller H, Catt M, Faber CG, Hapca A, Donnan PT, Gorman G, Bassez G, Schoser B, Knoop H, Treweek S, van Engelen BGM; OPTIMISTIC consortium. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurol. 2018 Aug;17(8):671-680. doi: 10.1016/S1474-4422(18)30203-5. Epub 2018 Jun 19.</citation>
    <PMID>29934199</PMID>
  </reference>
  <reference>
    <citation>Wenninger S, Montagnese F, Schoser B. Core Clinical Phenotypes in Myotonic Dystrophies. Front Neurol. 2018 May 2;9:303. doi: 10.3389/fneur.2018.00303. eCollection 2018. Review.</citation>
    <PMID>29770119</PMID>
  </reference>
  <reference>
    <citation>Wood L, Bassez G, van Engelen B, LochmÃ¼ller H, Schoser B; 222nd ENMC workshop participants. 222nd ENMC International Workshop:: Myotonic dystrophy, developing a European consortium for care and therapy, Naarden, The Netherlands, 1-2 July 2016. Neuromuscul Disord. 2018 May;28(5):463-469. doi: 10.1016/j.nmd.2018.02.003. Epub 2018 Feb 12.</citation>
    <PMID>29550152</PMID>
  </reference>
  <reference>
    <citation>Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B. Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol. 2017 Dec;264(12):2472-2480. doi: 10.1007/s00415-017-8653-2. Epub 2017 Oct 30.</citation>
    <PMID>29086017</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Benedikt Schoser</investigator_full_name>
    <investigator_title>Neurologist, senior physician</investigator_title>
  </responsible_party>
  <keyword>myotonic dystrophy type 2</keyword>
  <keyword>outcome scale</keyword>
  <keyword>muscle strength</keyword>
  <keyword>outcome measures</keyword>
  <keyword>disease specific severity scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

